Sunmax Biotechnology Co (ROCO:4728) EBIT: NT$1,019 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4728 Sunmax Biotechnology Co Ltd ROCO:4728
91 GF Score
Price NT$381.00
GF Value NT$441.22
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sunmax Biotechnology Co EBIT?

Sunmax Biotechnology Co ROCO:4728 +1.06% 91 EBIT is NT$1,019 Mil as of Dec. 2025. GuruFocus rates ROCO:4728 with a GF Score™ of 91/100 and a GF Value™ of NT$441.22 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Sunmax Biotechnology Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$218 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1,019 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sunmax Biotechnology Co's annualized ROC % for the quarter that ended in Dec. 2025 was 56.08%. Sunmax Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 95.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sunmax Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 5.12%.


Sunmax Biotechnology Co  (ROCO:4728) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sunmax Biotechnology Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=853.2 * ( 1 - 27.02% )/( (1083.427 + 1137.073)/ 2 )
=622.66536/1110.25
=56.08 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1898.779 - 126.317 - ( 736.093 - max(0, 241.379 - 930.414+736.093))
=1083.427

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2123.36 - 136.96 - ( 961.589 - max(0, 293.756 - 1143.083+961.589))
=1137.073

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sunmax Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=870.144/( ( (902.258 + max(-30.008, 0)) + (920.577 + max(-89.12, 0)) )/ 2 )
=870.144/( ( 902.258 + 920.577 )/ 2 )
=870.144/911.4175
=95.47 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.671 + 158.595 + 27.872) - (126.317 + 0 + 90.829)
=-30.008

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.605 + 152.662 + 25.901) - (136.96 + 0 + 131.328)
=-89.12

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sunmax Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=1019.459/19908.147
=5.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunmax Biotechnology Co EBIT Related Terms


Sunmax Biotechnology Co EBIT Historical Data

* Premium members only.

The historical data trend for Sunmax Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunmax Biotechnology Co EBIT Chart

Sunmax Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 360.29 778.52 793.47 959.23 1,019.46

Sunmax Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 201.24 315.66 220.22 266.04 217.54

ROCO:4728 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Sunmax Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunmax Biotechnology Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunmax Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunmax Biotechnology Co's EV-to-EBIT falls into.


ROCO:4728
91GF Score
Sunmax Biotechnology Co Ltd ROCO:4728
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunmax Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,019 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$1,019 Mil mean?
Sunmax Biotechnology Co (ROCO:4728) has a EBIT of NT$1,019 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunmax Biotechnology Co.
Is Sunmax Biotechnology Co's EBIT too high?
Sunmax Biotechnology Co's current EBIT is NT$1,019 Mil. Overall, Sunmax Biotechnology Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's EBIT compare to VRTX and REGN?
Sunmax Biotechnology Co's EBIT of NT$1,019 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunmax Biotechnology Co. Sunmax Biotechnology Co's current EBIT is NT$1,019 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$441.22, compared to a current price of NT$381.00 — trading 13.6% below its estimated fair value. The current EBIT is NT$1,019 Mil. Sunmax Biotechnology Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current EBIT is NT$1,019 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?

Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be undervalued. The current stock price of NT$381.00 is trading 13.6% below its estimated GF Value™ of NT$441.22. GuruFocus considers Sunmax Biotechnology Co to be Modestly Undervalued.

Key valuation signals for ROCO:4728:

  • EBIT: NT$1,019 Mil
  • GF Value™: NT$441.22 vs. price of NT$381.00 (13.6% below fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sunmax Biotechnology Co Business Description

Address Huandong Road, New Urban District, 1st Floor, No. 10, Lane 31, Section 1, Tainan Science Industrial Park, Tainan, TWN
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
91GF Score

Get the complete analysis for ROCO:4728

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$381.00
Price
NT$441.22
GF Value